JP2014058541A5 - - Google Patents

Download PDF

Info

Publication number
JP2014058541A5
JP2014058541A5 JP2013238416A JP2013238416A JP2014058541A5 JP 2014058541 A5 JP2014058541 A5 JP 2014058541A5 JP 2013238416 A JP2013238416 A JP 2013238416A JP 2013238416 A JP2013238416 A JP 2013238416A JP 2014058541 A5 JP2014058541 A5 JP 2014058541A5
Authority
JP
Japan
Prior art keywords
composition
polypeptide
subject
aaq66654
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013238416A
Other languages
Japanese (ja)
Other versions
JP2014058541A (en
Filing date
Publication date
Application filed filed Critical
Publication of JP2014058541A publication Critical patent/JP2014058541A/en
Publication of JP2014058541A5 publication Critical patent/JP2014058541A5/ja
Pending legal-status Critical Current

Links

Claims (14)

被験体におけるポルフィロモナス・ジンジバリスに対する免疫応答を生じさせる際に使用する組成物であって、免疫応答を生じさせるための有効量の、ＡＡＱ６６６５４、ＡＡＱ６５７４２、ＡＡＱ６６９９１、ＡＡＱ６５５６１、ＡＡＱ６６８３１、ＡＡＱ６６７９７、ＡＡＱ６６４６９、ＡＡＱ６６５８７、ＡＡＱ６６９７７、ＡＡＱ６５７９７、ＡＡＱ６５８６７、ＡＡＱ６５８６８、ＡＡＱ６５４１６、ＡＡＱ６５４４９、ＡＡＱ６６０５１、ＡＡＱ６６３７７、ＡＡＱ６６４４４、ＡＡＱ６６５３８、ＡＡＱ６７１１７及びＡＡＱ６７１１８から成る群から選択されるアクセッション番号に対応するポリペプチドの、少なくとも１つの抗原性部分又は免疫原性部分を含む、組成物。 A composition for use in generating an immune response against Porphyromonas gingivalis in a subject, in an effective amount for generating an immune response , AAQ66654, AAQ65742, AAQ65591, AAQ65631, AAQ66831, AAQ66797, AAQ66687 , An antigenic part corresponding to at least one antigenic part selected from the group consisting of: A composition comprising a protogenic moiety. 前記部分が、前記ポリペプチドの１つの少なくとも５０個のアミノ酸と実質的に同一であるアミノ酸配列を有する、請求項１に記載の組成物。 2. The composition of claim 1, wherein the portion has an amino acid sequence that is substantially identical to at least 50 amino acids of one of the polypeptides. 前記ポリペプチドが、ＡＡＱ６６６５４、ＡＡＱ６６９９１、ＡＡＱ６５５６１及びＡＡＱ６６８３１から成る群から選択されるアクセッション番号に対応する、請求項１又は２に記載の組成物。 The composition of claim 1 or 2, wherein the polypeptide corresponds to an accession number selected from the group consisting of AAQ66654, AAQ66991, AAQ65561 and AAQ66831. 前記ポリペプチドがアクセッション番号ＡＡＱ６６６５４に対応する、請求項１又は２に記載の組成物。 The composition according to claim 1 or 2, wherein the polypeptide corresponds to accession number AAQ66654 . 被験体におけるポルフィロモナス・ジンジバリスに対する免疫応答を生じさせる際に使用する組成物であって、免疫応答を生じさせるための有効量の、ポルフィロモナス・ジンジバリスにより発現され、且つＣＥＬＬＯプログラムにより細胞外にあることが予測されるポリペプチドの少なくとも５０個のアミノ酸と実質的に同一であるアミノ酸配列を有する少なくとも１つのポリペプチドを含む、組成物。 A composition for use in generating an immune response against Porphyromonas gingivalis in a subject, wherein the composition is expressed by Porphyromonas gingivalis in an effective amount to generate an immune response and is extracellular by the CELLO program A composition comprising at least one polypeptide having an amino acid sequence that is substantially identical to at least 50 amino acids of a polypeptide predicted to be in 被験体におけるポルフィロモナス・ジンジバリスに対する免疫応答を生じさせる際に使用する組成物であって、免疫応答を生じさせるための有効量の、マウス又はウサギにおいて免疫応答を引き起こすポリペプチドの少なくとも５０個のアミノ酸と実質的に同一である選択されたアミノ酸配列を有する少なくとも１つのポリペプチドを含む、組成物。 A composition for use in generating an immune response against Porphyromonas gingivalis in a subject, in an effective amount for generating an immune response, at least 50 of a polypeptide that elicits an immune response in a mouse or rabbit. A composition comprising at least one polypeptide having a selected amino acid sequence that is substantially identical to an amino acid. 被験体を歯周病に関して防止、抑制又は治療するための薬学的組成物であって、有効量の、請求項１〜６のいずれか一項に記載の組成物を含む、薬学的組成物。 Preventing a subject with respect to periodontal disease, a pharmaceutical composition for inhibiting or treating effective amount of, including a composition according to any one of claims 1 to 6, pharmaceutical compositions . 被験体をポルフィロモナス・ジンジバリス感染症に関して防止又は治療するための薬学的組成物であって、請求項１〜７のいずれか一項に記載の組成物を含む、薬学的組成物。 A pharmaceutical composition for preventing or treating a subject with respect to P. gingivalis infection, the composition including, pharmaceutical composition according to any one of claims 1 to 7. アクセッション番号ＡＡＱ６６６５４、ＡＡＱ６５７４２、ＡＡＱ６６９９１、ＡＡＱ６５５６１、ＡＡＱ６６８３１、ＡＡＱ６６７９７、ＡＡＱ６６４６９、ＡＡＱ６６５８７、ＡＡＱ６６９７７、ＡＡＱ６５７９７、ＡＡＱ６５８６７、ＡＡＱ６５８６８、ＡＡＱ６５４１６、ＡＡＱ６５４４９、ＡＡＱ６６０５１、ＡＡＱ６６３７７、ＡＡＱ６６４４４、ＡＡＱ６６５３８、ＡＡＱ６７１１７及びＡＡＱ６７１１８に対応するポリペプチドの１つの少なくとも５０個のアミノ酸と実質的に同一であるアミノ酸配列を有する、該ポリペプチドの抗原性領域に対して産生される抗体。 Accession number AAQ66654, AAQ65742, AAQ66991, AAQ65561, AAQ66831, AAQ66797, AAQ66469, AAQ66587, A AQ66977, AAQ65797, AAQ65867, AAQ65868, AAQ65416, AAQ65449, AAQ66051, AAQ66377, AAQ66444, AAQ66538, 1 polypeptide corresponding to AAQ67117 and AAQ67118 An antibody raised against an antigenic region of the polypeptide having an amino acid sequence substantially identical to at least 50 amino acids. 前記ポリペプチドが、ＡＡＱ６６６５４、ＡＡＱ６６９９１、ＡＡＱ６５５６１及びＡＡＱ６６８３１から成る群から選択されるアクセッション番号に対応する、請求項９に記載の抗体。 10. The antibody of claim 9, wherein the polypeptide corresponds to an accession number selected from the group consisting of AAQ66654, AAQ66991, AAQ65561 and AAQ66831. 前記ポリペプチドがアクセッション番号ＡＡＱ６６６５４に対応する、請求項９に記載の抗体。 10. The antibody of claim 9, wherein the polypeptide corresponds to accession number AAQ66654 . ポルフィロモナス・ジンジバリス感染症又は歯周病を、それを必要としている被検体において治療又は予防するための薬物の製造における、請求項１〜６のいずれか１項に記載の組成物の使用。Use of the composition according to any one of claims 1 to 6 in the manufacture of a medicament for treating or preventing Porphyromonas gingivalis infection or periodontal disease in a subject in need thereof. ポルフィロモナス・ジンジバリス感染症又は歯周病を、それを必要としている被検体において治療又は予防するための薬物の製造における、請求項９〜１１のいずれか１項に記載の抗体の使用。Use of the antibody according to any one of claims 9 to 11 in the manufacture of a medicament for treating or preventing Porphyromonas gingivalis infection or periodontal disease in a subject in need thereof. ポルフィロモナス・ジンジバリス感染症又は歯周病を、それを必要としている被検体において治療又は予防するための薬物の製造における、アクセッション番号ＡＡＱ６６６５４に対応するポリペプチドの、少なくとも１つの抗原性部分又は免疫原性部分の使用。At least one antigenic portion of a polypeptide corresponding to accession number AAQ66654 in the manufacture of a medicament for treating or preventing Porphyromonas gingivalis infection or periodontal disease in a subject in need thereof, or Use of an immunogenic moiety.
JP2013238416A 2007-07-12 2013-11-19 Immunology treatment for biofilms Pending JP2014058541A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007903787A AU2007903787A0 (en) 2007-07-12 Immunology treatment for biofilms
AU2007903787 2007-07-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010515320A Division JP2010532766A (en) 2007-07-12 2008-07-11 Immunological treatment for biofilm

Publications (2)

Publication Number Publication Date
JP2014058541A JP2014058541A (en) 2014-04-03
JP2014058541A5 true JP2014058541A5 (en) 2014-05-15

Family

ID=40228121

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010515320A Pending JP2010532766A (en) 2007-07-12 2008-07-11 Immunological treatment for biofilm
JP2013238416A Pending JP2014058541A (en) 2007-07-12 2013-11-19 Immunology treatment for biofilms

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010515320A Pending JP2010532766A (en) 2007-07-12 2008-07-11 Immunological treatment for biofilm

Country Status (10)

Country Link
US (2) US20100297179A1 (en)
EP (2) EP2604692A1 (en)
JP (2) JP2010532766A (en)
KR (1) KR20100071964A (en)
CN (2) CN101842486A (en)
AU (1) AU2008274907B2 (en)
CA (1) CA2693717A1 (en)
NZ (3) NZ595378A (en)
SG (1) SG182988A1 (en)
WO (1) WO2009006700A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
EP2038297A4 (en) 2006-06-27 2010-03-03 Oral Health Australia Pty Ltd Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
US8241611B2 (en) 2007-07-12 2012-08-14 Oral Health Austrailia Pty. Ltd. Biofilm treatment
CA2735171C (en) 2008-08-29 2023-10-03 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of p.gingivalis infection
AU2010281313B2 (en) * 2009-08-02 2015-09-03 Sanofi Pasteur Limited Porphyromonas gingivalis polypeptides
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
CN105418758A (en) * 2015-12-03 2016-03-23 沈阳惠民生物技术有限公司 Preparation method and application of anti-periodontosis antibody
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN113005069B (en) * 2021-01-28 2023-09-26 广东海洋大学 Attenuated Nocardia quinquebrachii and preparation method and application thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210035A (en) 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5830710A (en) 1988-09-08 1998-11-03 University Of Florida Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease
WO1994027606A1 (en) 1993-05-28 1994-12-08 Unisearch Limited Method of treating helicobacter pylori infection
CN1126433A (en) * 1993-06-28 1996-07-10 狮子株式会社 Composition for oral cavity
US5523390A (en) * 1993-09-10 1996-06-04 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
US5475097A (en) * 1993-10-21 1995-12-12 University Of Georgia Research Foundation, Inc. Lysine-specific Porphyromonas gingivalis proteinase
US6017532A (en) * 1993-09-10 2000-01-25 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
DE69432795T2 (en) 1993-09-10 2004-04-29 University Of Georgia Research Foundation, Inc. PORPHYROMONAS GINGIVALIS ARGININE-SPECIFIC PROTEINASE-ENCODING SEQUENCES
JPH0797395A (en) 1993-09-28 1995-04-11 Kyowa Medex Co Ltd Peptides containing sequence of porphyromonas gingivalis cilium protein and its use
DE69527514T2 (en) 1994-03-29 2003-04-03 Meito Sangyo Kk GENE OF A CELL SURFACE POLYPEPTIDE
AUPN627595A0 (en) * 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
WO1997034629A1 (en) 1996-03-22 1997-09-25 University Of Georgia Research Foundation, Inc. Immunogenic compositions comprising porphyromonas gingivalis peptides and methods
AUPN901296A0 (en) * 1996-03-29 1996-04-26 University Of Melbourne, The Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) * 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
AU1648799A (en) * 1997-12-10 1999-06-28 Csl Limited (porphorymonas gingivalis) polypeptides and nucleotides
US8129500B2 (en) * 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
AUPP083997A0 (en) * 1997-12-10 1998-01-08 Csl Limited Porphyromonas gingivalis nucleotides
US6444799B1 (en) * 1997-12-31 2002-09-03 Csl Limited P. gingivalis polynucleotides and uses thereof
AUPP893999A0 (en) * 1999-03-01 1999-03-25 Csl Limited Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
GB9913437D0 (en) 1999-06-09 1999-08-11 Medical Res Council Fusion proteins
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
AUPQ718200A0 (en) * 2000-04-28 2000-05-25 Csl Limited Porphyromonas gingivalis recombinant proteins and truncations
US6576226B1 (en) * 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US20030083287A1 (en) 2000-11-30 2003-05-01 Burgess Nicola A. ginS
GB2381449A (en) 2001-10-31 2003-05-07 Smithkline Beecham Plc Oral hygiene compositions comprising an electron acceptor
JP2003192616A (en) 2001-12-27 2003-07-09 Univ Nihon Dna vaccine for periodontal disease
JP2003286191A (en) 2002-03-27 2003-10-07 Univ Nihon Mucosal immune vaccine for periodontal disease
WO2004083425A1 (en) 2003-03-17 2004-09-30 Kirin Beer Kabushiki Kaisha Remedy for periodontal disease
WO2005019249A2 (en) * 2003-08-15 2005-03-03 University Of Florida Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
US7424370B2 (en) * 2004-02-06 2008-09-09 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
EP1799705A4 (en) * 2004-09-23 2008-11-05 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
WO2008016385A2 (en) * 2006-01-20 2008-02-07 The University Of Washington Deacylase polypeptides, deacylase polynucleotides, and methods of use thereof
EP2038297A4 (en) * 2006-06-27 2010-03-03 Oral Health Australia Pty Ltd Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
WO2008124646A2 (en) 2007-04-06 2008-10-16 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Use of amyloid proteins as vaccine scaffolds
US8241611B2 (en) * 2007-07-12 2012-08-14 Oral Health Austrailia Pty. Ltd. Biofilm treatment
JP2012530073A (en) * 2009-06-19 2012-11-29 オーラル ヘルス オーストラリア ピーティーワイ リミテッド Casein-derived protease inhibitor peptide

Similar Documents

Publication Publication Date Title
JP2014058541A5 (en)
JP2010532766A5 (en)
CL2018000232A1 (en) Peptide mixture (divisional application 201601405)
JP2015514395A5 (en)
AR118560A2 (en) METHODS AND COMPOSITIONS INCLUDING PURIFIED RECOMBINANT POLYPEPTIDES
EA202090919A1 (en) Lipid Nanoparticles for the Delivery of Modified RNA Encoding VEGF-A POLYPEPTIDE
MX2022006107A (en) Methods and compositions for dosing in adoptive cell therapy.
RU2017104529A (en) COMPOSITIONS OF NEISSERIA MENINGITIDIS AND WAYS OF THEIR APPLICATION
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
HRP20220717T1 (en) Modified mrna compositions
JP2013172734A5 (en)
IN2014KN01713A (en)
MX342716B (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease.
EA202090053A2 (en) METHODS AND COMPOSITIONS FOR TREATING NON-EFFECTIVE ERYTHROPOESIS
WO2014160463A8 (en) Prefusion rsv f proteins and their use
JP2014513951A5 (en)
JP2015517488A5 (en)
MX360211B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
HRP20191291T1 (en) Immunogenic composition
BR112015022197A8 (en) use of a compound for the manufacture of a medicament or pharmaceutical composition for treating cataplexy
BR112015030644A2 (en) COMPOSITIONS OF CONTINUOUSLY OVERLAPING PEPTIDES, AS WELL AS PEPTIDES AND THEIR USE IN THE TREATMENT OF ALLERGY TO HOUSEDUST MITE
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CL2012003458A1 (en) Vector comprising a campylobacter antigenic polypeptide; pharmaceutical composition comprising said vector; use of the vector to improve the subject's immune response to the antigenic polypeptide.
AR092993A1 (en) LAQUINIMOD TO REDUCE TALAMIC DAMAGE IN MULTIPLE SCLEROSIS
BR112015031417A8 (en) pharmaceutical dosage form, pharmaceutical composition, methods for treating a patient in need of cysteamine and for preparing a dosage form